These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Prognostic models predicting transition to psychotic disorder using blood-based biomarkers: a systematic review and critical appraisal. Byrne JF; Mongan D; Murphy J; Healy C; Fӧcking M; Cannon M; Cotter DR Transl Psychiatry; 2023 Oct; 13(1):333. PubMed ID: 37898606 [TBL] [Abstract][Full Text] [Related]
4. Risk Prediction Models for Hospital Mortality in General Medical Patients: A Systematic Review. Hydoub YM; Walker AP; Kirchoff RW; Alzu'bi HM; Chipi PY; Gerberi DJ; Burton MC; Murad MH; Dugani SB Am J Med Open; 2023 Dec; 10():. PubMed ID: 38090393 [TBL] [Abstract][Full Text] [Related]
5. Systematic Review and Critical Appraisal of Prediction Models for Readmission in Coronary Artery Disease Patients: Assessing Current Efficacy and Future Directions. Zhang Y; Zhu X; Gao F; Yang S Risk Manag Healthc Policy; 2024; 17():549-557. PubMed ID: 38496372 [TBL] [Abstract][Full Text] [Related]
6. Factors associated with relapses in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis. Xie Y; Tian Z; Han F; Liang S; Gao Y; Wu D Medicine (Baltimore); 2020 Jul; 99(27):e20885. PubMed ID: 32629678 [TBL] [Abstract][Full Text] [Related]
7. The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. Sorensen PS; Sellebjerg F; Hartung HP; Montalban X; Comi G; Tintoré M Brain; 2020 Sep; 143(9):2637-2652. PubMed ID: 32710096 [TBL] [Abstract][Full Text] [Related]
8. The prevalence of migraine in multiple sclerosis (MS): A systematic review and meta-analysis. Mirmosayyeb O; Barzegar M; Nehzat N; Shaygannejad V; Sahraian MA; Ghajarzadeh M J Clin Neurosci; 2020 Sep; 79():33-38. PubMed ID: 33070914 [TBL] [Abstract][Full Text] [Related]
9. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Amato MP; Fonderico M; Portaccio E; Pastò L; Razzolini L; Prestipino E; Bellinvia A; Tudisco L; Fratangelo R; Comi G; Patti F; De Luca G; Brescia Morra V; Cocco E; Pozzilli C; Sola P; Bergamaschi R; Salemi G; Inglese M; Millefiorini E; Galgani S; Zaffaroni M; Ghezzi A; Salvetti M; Lus G; Florio C; Totaro R; Granella F; Vianello M; Gatto M; Di Battista G; Aguglia U; Logullo FO; Simone M; Lucisano G; Iaffaldano P; Trojano M Brain; 2020 Oct; 143(10):3013-3024. PubMed ID: 32935843 [TBL] [Abstract][Full Text] [Related]
10. Risk of cancer in multiple sclerosis (MS): A systematic review and meta-analysis. Ghajarzadeh M; Mohammadi A; Sahraian MA Autoimmun Rev; 2020 Oct; 19(10):102650. PubMed ID: 32801049 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of rituximab in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis. Tian X; Chen C; Ma L; Wei R; Li M; Wang X; Wu Y; Zhou Y; Cui Y J Neuroimmunol; 2020 Oct; 347():577317. PubMed ID: 32731048 [TBL] [Abstract][Full Text] [Related]
12. Reliability in long-term clinical studies of disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review. Lucchetta RC; Leonart LP; Gonçalves MVM; Becker J; Pontarolo R; Fernandez-Llimós F; Wiens A PLoS One; 2020; 15(6):e0231722. PubMed ID: 32544164 [TBL] [Abstract][Full Text] [Related]
13. How patients with multiple sclerosis acquire disability. Lublin FD; Häring DA; Ganjgahi H; Ocampo A; Hatami F; Čuklina J; Aarden P; Dahlke F; Arnold DL; Wiendl H; Chitnis T; Nichols TE; Kieseier BC; Bermel RA Brain; 2022 Sep; 145(9):3147-3161. PubMed ID: 35104840 [TBL] [Abstract][Full Text] [Related]
14. Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study. De Brouwer E; Becker T; Werthen-Brabants L; Dewulf P; Iliadis D; Dekeyser C; Laureys G; Van Wijmeersch B; Popescu V; Dhaene T; Deschrijver D; Waegeman W; De Baets B; Stock M; Horakova D; Patti F; Izquierdo G; Eichau S; Girard M; Prat A; Lugaresi A; Grammond P; Kalincik T; Alroughani R; Grand'Maison F; Skibina O; Terzi M; Lechner-Scott J; Gerlach O; Khoury SJ; Cartechini E; Van Pesch V; Sà MJ; Weinstock-Guttman B; Blanco Y; Ampapa R; Spitaleri D; Solaro C; Maimone D; Soysal A; Iuliano G; Gouider R; Castillo-Triviño T; Sánchez-Menoyo JL; Laureys G; van der Walt A; Oh J; Aguera-Morales E; Altintas A; Al-Asmi A; de Gans K; Fragoso Y; Csepany T; Hodgkinson S; Deri N; Al-Harbi T; Taylor B; Gray O; Lalive P; Rozsa C; McGuigan C; Kermode A; Sempere AP; Mihaela S; Simo M; Hardy T; Decoo D; Hughes S; Grigoriadis N; Sas A; Vella N; Moreau Y; Peeters L PLOS Digit Health; 2024 Jul; 3(7):e0000533. PubMed ID: 39052668 [TBL] [Abstract][Full Text] [Related]
16. Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis. Reeve K; On BI; Havla J; Burns J; Gosteli-Peter MA; Alabsawi A; Alayash Z; Götschi A; Seibold H; Mansmann U; Held U Cochrane Database Syst Rev; 2023 Sep; 9(9):CD013606. PubMed ID: 37681561 [TBL] [Abstract][Full Text] [Related]
17. Understanding who benefits most from cognitive rehabilitation for multiple sclerosis: A secondary data analysis. Taylor LA; Mhizha-Murira JR; Law G; Evangelou N; das Nair R Mult Scler; 2023 Oct; 29(11-12):1482-1492. PubMed ID: 37528618 [TBL] [Abstract][Full Text] [Related]
18. TSPO-Detectable Chronic Active Lesions Predict Disease Progression in Multiple Sclerosis. Polvinen E; Matilainen M; Nylund M; Sucksdorff M; Airas LM Neurol Neuroimmunol Neuroinflamm; 2023 Sep; 10(5):. PubMed ID: 37349108 [TBL] [Abstract][Full Text] [Related]
19. Retrospective cohort study to devise a treatment decision score predicting adverse 24-month radiological activity in early multiple sclerosis. Hapfelmeier A; On BI; Mühlau M; Kirschke JS; Berthele A; Gasperi C; Mansmann U; Wuschek A; Bussas M; Boeker M; Bayas A; Senel M; Havla J; Kowarik MC; Kuhn K; Gatz I; Spengler H; Wiestler B; Grundl L; Sepp D; Hemmer B Ther Adv Neurol Disord; 2023; 16():17562864231161892. PubMed ID: 36993939 [TBL] [Abstract][Full Text] [Related]